Table 1. Patients’ General Characteristics and Distribution Between Groupsa,b.
| Variables | Trial Groups | P Value | ||
|---|---|---|---|---|
| Placebo | 15 mg/kg GABA | 30 mg/kg GABA | ||
| GenderA | 0.772 | |||
| Male | 29 (64.4) | 29 (65.9) | 27 (58.7) | |
| Female | 16 (35.6) | 15 (34.1) | 19 (41.3) | |
| AgeB, y | 3.15 ± 1.47 (1 - 5.9) | 3.29 ± 1.42 (1-6) | 3.42 ± 1.39 (1 - 6) | 0.647 |
| WeightB, kg | 16.26 ± 5.43 (3.5 - 32.1) | 16.47 ± 4.36 (9 - 27) | 16.67 ± 4.12 (10 - 32.1) | 0.848 |
| Number of previous procedures | 0.082 | |||
| 0 - 3 | 30 (66.7) | 23 (53.5) | 20 (43.5) | |
| ≥ 4 | 15 (33.3) | 20 (46.5) | 26 (56.5) | |
| Type of procedureA | 0.935 | |||
| Myelogram | 15 (33.3) | 12 (27.3) | 16 (34.8) | |
| Lumbar puncture | 26 (57.8) | 28 (63.6) | 25 (54.3) | |
| Myelogram + lumbar puncture | 4 (8.9) | 4 (9.1) | 5 (10.9) | |
| ChemotherapyA | 0.991 | |||
| Yes | 27 (60.0) | 27 (61.4) | 28 (60.9) | |
| No | 18 (40.0) | 17 (38.6) | 18 (39.1) | |
aValues are expressed as mean ± SD or No. (%).
bThe general characteristics of patients (gender, age, weight), type of procedure, frequency of procedure, and the use of chemotherapy on the day of experiment did not show any distributive discrepancy between the placebo, 15 mg/kg GABA, and 30 mg/kg GABA groups (P > 0.05 based on chi-square test (χ2) and Kruskal-Wallis test).